Overview of Cleocin Vaginal Ovules

Quick Facts

Property	Description
Active ingredient	Clindamycin phosphate
Form	Vaginal ovule (Vaginal suppository)
Pharmacological class	Lincosamide antibiotic
Common use	Anti-infective treatment
Origin	Semisynthetic

What Type of Medicine is Cleocin Vaginal Ovules?

Cleocin Vaginal Ovules is a specific prescription medicine (Rx) containing the active ingredient Clindamycin phosphate, which belongs to the lincosamide antibiotic class and acts as an antibacterial agent. Clindamycin is chemically defined as a semisynthetic compound, derived from the antibiotic Lincomycin to optimize its profile against susceptible microorganisms. The identity as a lincosamide is clinically recognized for providing an effective approach to bacterial concerns, especially when targeting bacteria exhibiting specific sensitivities.

Composition and Form: The Vaginal Ovule

The preparation utilizes a specialized vaginal ovule format, structurally known as a vaginal suppository, which is a semi-solid dosage form created for local drug delivery via the vaginal route of administration. This single-ingredient product is distinguished by its unit-dose application, where the active Clindamycin phosphate is incorporated into a suppository base that melts after insertion. The advantage of this ovule form is its structural consistency, which assists in uniform drug exposure at the site of concern, a feature valued in targeted anti-infective treatments. This localized delivery is essential for maximizing therapeutic effect while ensuring minimal systemic absorption.

General Purpose of Clindamycin as an Anti-Infective

The general purpose of the Clindamycin phosphate active ingredient is to serve as an anti-infective by acting directly on susceptible bacterial species. Its core function is rooted in the inhibition of bacterial protein synthesis, a mechanism that interferes with the ability of bacteria to grow and replicate. This process involves the drug binding to the bacterial 50S ribosomal subunit, ultimately eliminating the population of target organisms. This mechanism is primarily utilized in situations requiring the reduction of specific bacterial populations and the subsequent resolution of microbial imbalance in the vagina.

Regulatory References

MedlinePlus Drug Information: Clindamycin

What side effects are possible with Cleocin Vaginal Ovules?

Possible side effects and safety information

Adverse Reaction Scope

The official safety profile of this medicine focuses on both expected local effects and the potential for serious, systemic reactions associated with the clindamycin class. Approximately 3% of the dose is absorbed into the bloodstream, which is substantially lower than oral forms, but supports the possibility of systemic effects.

Category	Officially Documented Effects
Common Effects	Vulvovaginal candidiasis (yeast infection), vaginal pain, vulvovaginal disorder, headache, abdominal pain, nausea, and diarrhea.
Serious Adverse Reactions	Clostridioides difficile-associated diarrhea (CDAD): This potentially fatal colitis is a mandatory warning for the clindamycin class. Symptoms, including bloody diarrhea, may occur during or after treatment. Severe hypersensitivity reactions, including anaphylaxis and rare skin reactions resembling Stevens-Johnson syndrome, are also documented.

Regulatory Safety Considerations

Safety Restrictions and Contraindications

Use of this medicine is formally restricted in individuals with a history of sensitivity to clindamycin or lincomycin, as well as those with pre-existing gastrointestinal conditions such as regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Population-Specific Notes

Pregnancy: Use in the first trimester should occur only when clearly needed. The safety and effectiveness have not been established for use in pediatric patients.
Lactation: The drug is excreted into breast milk, and official documents note the potential for effects on the nursing infant's gastrointestinal flora, such as diarrhea or candidiasis.

Context-of-Use Safety Notes

The ovule base contains an oleaginous component that may weaken latex or rubber products, such as condoms or vaginal contraceptive diaphragms. The use of this medicine may also result in the overgrowth of non-susceptible organisms in the vagina, which may manifest as a fungal infection.

The regulatory safety structure formally outlines the expected common local reactions alongside the high-level, class-specific systemic risks like CDAD. This framework defines the necessary usage constraints tied to prior disease history and allergic status.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile notes that Cleocin Vaginal Ovules, containing Clindamycin phosphate, could be absorbed in sufficient amounts to produce systemic effects in an overdose scenario. This risk is acknowledged because the active ingredient is an antibacterial agent with systemic activity.

Documented Overdose Manifestations

The most serious documented systemic complication is Pseudomembranous colitis, which regulators classify as potentially life-threatening. Manifestations can include severe abdominal pain and bloody or watery diarrhea subsequent to administration. Other documented effects from systemic exposure may include abnormalities in liver function, such as jaundice, and changes in the blood, such as transient neutropenia.

Required Emergency Actions

In case of suspected overdose or accidental oral ingestion, contact with the Poison Control helpline is required. Immediate medical attention must be sought if signs of severe systemic effects occur. Regulators mandate calling emergency services (911) if the individual is collapsed, experiencing a seizure, has trouble breathing, or cannot be awakened. Treatment primarily focuses on symptomatic and supportive measures, as no specific antidote is known, and procedures like hemodialysis are documented as ineffective for removal.

Therapeutic Uses of Cleocin Vaginal Ovules

What Cleocin Vaginal Ovules Treats: Main Uses and Benefits

Key Therapeutic Focus

The primary therapeutic role of this prescription ovule is the specific treatment of Bacterial Vaginosis (BV) in non-pregnant women. This anti-infective is applied across clinical settings that involve acute or unstable symptom patterns. The central purpose of Cleocin Vaginal Ovules is used for managing the bacterial imbalance associated with BV. This is relevant in conditions characterized by periods of heightened symptoms, where the medication is commonly used to help with the microbial environment. The core benefit supports the management of the underlying infection, which helps maintain a sense of stability when symptoms are more noticeable.

Symptom Relief and Patient Comfort

The therapy is commonly used to help manage symptom clusters that interfere with daily comfort. The primary symptom clusters that the medication addresses involve abnormal discharge and malodor concerns. By addressing these acute manifestations, this local therapy provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

“This medication is commonly used to help manage symptoms, supporting patients during difficult episodes by easing distress.”

Quick Fact: Support for Malodor Concerns The medication is used for managing the source of the distinctive and often bothersome malodor concerns, offering supportive relief during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cleocin Vaginal Ovules

The eligibility for using Cleocin Vaginal Ovules (clindamycin phosphate) is strictly defined by regulatory documents, focusing on patient history and physiological status. The medicine is primarily allowed for use in non-pregnant women for its labeled indication.

Absolute Contraindications

Use is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin, or to any component of the ovule. Additionally, the medicine must not be used by patients with a history of specific gastrointestinal conditions, including regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Population Restrictions and Limitations

Population Group	Eligibility Status (Regulatory Wording)
Pre-menarchal females	Safety and efficacy have not been established (Not Established)
Pregnancy (First Trimester)	Restricted; use only if clearly needed and benefits outweigh risks (Conditional Use)
Lactation (Nursing Mothers)	Conditional; an alternate drug may be preferred (Use with Caution)
Concurrent Activities	Vaginal intercourse, tampons, or douches are prohibited during treatment (Restriction)
Latex/Rubber Products	Use not recommended within 72 hours following treatment (Conditional Restriction)

No specific dose adjustments are defined in the ovule label for patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Cleocin Vaginal Ovules details specific interaction constraints and prohibitions with other medicines and certain products. This information is classified based on the nature of the interaction as documented in official prescribing information.

Pharmacodynamic and Medicinal Interactions

The active ingredient, clindamycin, possesses intrinsic neuromuscular blocking properties. Due to this characteristic, co-administration with other neuromuscular blocking agents may result in an enhanced action of the blocking agent. Official labeling advises caution when this combination is utilized due to the potential for increased pharmacodynamic effect.

A combination strictly classified as contraindicated by regulatory authorities is co-administration with the lincosamide analogue Lincomycin. This prohibition is based on a known risk of cross-hypersensitivity between the two compounds.

Physical Compatibility and Timing Restrictions

Due to the specialized semi-solid formulation, a timing-based interaction rule is necessary for certain products. The ovule is manufactured using an oleaginous base which has the potential to weaken materials like latex or rubber. Therefore, the use of latex or rubber products—specifically condoms or vaginal contraceptive diaphragms—is not recommended for a period of 72 hours following the administration of the ovule to ensure product integrity and function.

No specific metabolic (CYP-mediated) or food/alcohol interactions are documented in the official regulatory information for this vaginal formulation.

Mechanism of Action

The mechanism of action of Clindamycin involves the suppression of susceptible bacteria by disrupting their ability to synthesize essential proteins.

Targeting the Bacterial Protein Factory

The active ingredient, Clindamycin, acts by forming a selective, reversible bond with the bacterial 50S ribosomal subunit . This molecular binding event, occurring at the 23S ribosomal RNA, blocks the peptidyl transferase center and the ribosomal translocation process. This molecular interference results in the inhibition of pathogen proliferation, preventing the pathogen from assembling the structural and enzymatic proteins needed for growth and division.

Local Microbial Ecosystem Modulation

By suppressing the growth and leading to the elimination of the susceptible bacterial populations, the drug's mechanism initiates a physiological shift within the site of administration. This action locally influences the composition of the microbial ecosystem by reducing the density of specific target organisms. The consequence is local antimicrobial action influencing the composition of the microbial ecosystem.

Dosage and Administration Information

Official Administration Guidelines

The usage of Cleocin Vaginal Ovules is defined by a specific, short-term protocol outlined in official prescribing information.

Dosing and Route

The medicine is designed exclusively for intravaginal administration and must not be taken by mouth. The labeled dose is one 100 mg ovule of clindamycin (as clindamycin phosphate) per application, intended for non-pregnant women.

Property	Administration Detail
Unit Dose	One 100 mg ovule
Frequency	Once daily (QD)
Duration	3 consecutive days

Procedural Timing and Constraints

The official schedule requires the ovule to be administered preferably at bedtime. This timing is designed to support maximum local drug retention, as the ovule base melts after insertion.

Administration includes mandatory avoidance patterns: the use of other vaginal products, such as douches or tampons, is not advised during the three-day course. Furthermore, the base material in the ovule formulation may weaken latex or rubber products; therefore, the use of latex barrier products (e.g., condoms or diaphragms) is officially not recommended within 72 hours following completion of the treatment course. The ovule is a unit-dose form that requires no external preparation.

Recent Clinical Evidence

Cleocin Vaginal Ovules: Recent Clinical Evidence

Evidence for Use in Bacterial Vaginosis (BV)

The evidence base primarily relies on Randomized Controlled Trials (RCTs) used in the regulatory process to explore how symptoms change over time in non-pregnant women diagnosed with Bacterial Vaginosis (BV). These studies monitored specific changes in the observed populations, with researchers primarily focused on a composite outcome known as "clinical status." This included monitoring the return of vaginal pH to normal levels, the absence of the distinctive amine odor, and the absence of specific cells (clue cells) when examined under a microscope. The trials reported the patterns of change observed for this composite outcome measurement, and this research provided insight into changes in microbial balance monitored during the study period.

Comparing Treatments in Clinical Trials

The research examined the use of the ovule against active comparator medications. Studies focused on episodes where symptoms become more noticeable and monitored how the ovule performed relative to an established 7-day clindamycin vaginal cream regimen and an oral metronidazole regimen. This research explored short-term symptom changes and helped contextualize how patients reported their experience when using different delivery forms of treatment.

Long-Term Evidence and Follow-Up

Research exploring short-term symptom changes typically monitored patient outcomes over a limited duration. The primary efficacy assessments in the pivotal trials were conducted at an intermediate-term follow-up, approximately one month after the start of treatment. While the one-month data describes the short-term patterns observed, the follow-up durations were limited, meaning that long-term effects on the recurrence of BV or on sustained daily functioning are not fully established. It is not yet clear how study findings relate to the frequency of BV recurrence.

Research in Specific Patient Populations

The primary clinical trials were applied in research contexts involving women generally between the ages of 16 and 60. The results apply only to the populations studied. The data for certain groups remain insufficient; the evidence highlights what is still uncertain, particularly for women who fall outside the core study population. For example, research describing the use of the ovule has specifically excluded pregnant women, so evidence is limited for this population. Similarly, the safety and whether it can be evaluated in pre-menarchal females have not been established in research settings.

Areas of Research Uncertainty and Gaps

The evidence quality varies across studies, and findings describe group patterns, not personal outcomes. Several key limitations were noted in the evidence used for regulatory review, including challenges with patient follow-up that resulted in a number of participants not being fully evaluated for the main outcome. Due to the limited information for long-term outcomes, the certainty remains low regarding the ovule’s role in influencing the recurrence of BV. The existing evidence is limited and cannot fully provide insight into long-term changes, especially for special populations where data is scarce.

Frequently Asked Questions (FAQ)

Common questions about Cleocin Vaginal Ovules (FAQ)

Q: Do Cleocin Vaginal Ovules treat yeast infections?

According to official prescribing information, this medicine is indicated for treating bacterial vaginosis (BV). It is important to note that vulvovaginal candidiasis, which is another name for a yeast infection, is officially documented as a common side effect that may occur while using this medication.

Q: How fast does the medication start working after inserting the ovule?

The official research that supports the drug's use monitored changes over a defined time period. The primary assessments for determining clinical status were generally conducted at approximately one month after the treatment course began.

Q: Is it normal to have a change in discharge after using the ovule?

The ovule is a semi-solid medicine designed with a base of saturated fatty acid glycerides that is intended to melt after insertion. This melting action may result in residue or discharge. Official reports also list vaginal discharge and vulvovaginal disorder as common, documented effects.

Q: Does using this medicine affect birth control pills?

The official regulatory information for this specific vaginal formulation does not document metabolic (CYP-mediated) drug interactions with other medicines, which includes the mechanism used by most oral hormonal contraceptives. However, the ovule base may weaken latex barrier products, such as condoms or diaphragms.

Q: Can I use other vaginal products (like douches or washes) at the same time?

Official administration instructions state that the use of other vaginal products, such as douches or tampons, is officially not recommended during the three-day treatment course.

Q: Is it okay to use this if I have a history of colitis?

Use of the medicine is formally contraindicated (not permitted by regulatory instruction) for individuals who have a history of certain gastrointestinal conditions. This includes a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Q: What is the distinction between this ovule and a suppository?

According to official documentation, the product is structurally defined as a vaginal ovule (Vaginal suppository). This indicates that the terms are often used interchangeably to describe this specific type of unit-dose, semi-solid medication designed for local vaginal delivery.

Q: Can Cleocin Vaginal Ovules interact with blood thinners?

The official regulatory information for this formulation only lists two specific drug interactions: caution with neuromuscular blocking agents and a contraindication with lincomycin. It does not document specific drug interactions between this formulation and commonly used blood thinners (anticoagulants).

Q: Do Cleocin Vaginal Ovules cause a yeast infection?

Official adverse reaction reporting lists vulvovaginal candidiasis (yeast infection) as a common side effect that is documented to occur during or after treatment. This is related to the drug's effect on the microbial balance at the site of administration.

Q: What happens if I stop using the ovules before the course is finished?

Official prescribing information indicates a recommended course of 3 consecutive days of treatment. The use of this medicine may result in the overgrowth of non-susceptible organisms if the full course is not completed.

Q: How does the medicine know where to go once I put it in?

The ovule is a specialized semi-solid dosage form formulated for local drug delivery via the vaginal route. This design is intended to maximize the therapeutic effect at the site of concern, while minimizing systemic absorption (absorption into the rest of the body).

Q: What are the ingredients in the ovule besides the active drug?

The active ingredient is clindamycin phosphate, which is incorporated into a suppository base. Official descriptions state this base consists of a mixture of glycerides of saturated fatty acids.

Q: Why does the packaging say this drug is an 'ovule'?

The term ovule is used to describe its specific physical form and function as a semi-solid vaginal suppository created for local drug delivery. This form is specifically designed to melt and aid in the uniform release of the drug at the site of concern.

Q: How soon after treatment is it safe to resume normal activities?

The only mandatory timing restriction officially documented following treatment involves specific barrier contraceptives. The use of latex barrier products (e.g., condoms or diaphragms) is officially not recommended for a period of 72 hours after completing the treatment course.

Q: How common is it for the original infection to come back after treatment?

The official research evidence notes that certainty is limited regarding the ovule’s specific role in influencing the long-term recurrence of BV. The follow-up durations used in the pivotal clinical trials were limited, meaning long-term data on recurrence are not fully established.

Q: Does the ovule melt completely, or is some residue expected?

The ovule is a semi-solid dosage form with an oleaginous base that is designed to melt after insertion. This melting process ensures the drug is released locally, and it may result in residue or discharge.

Q: Can men also use Cleocin Vaginal Ovules?

The medicine is indicated and dosed exclusively for intravaginal administration. The official labeling specifies its use for the treatment of bacterial vaginosis in non-pregnant women.

Q: Are there any age restrictions for using this medicine?

Official regulatory documents state that the safety and effectiveness have not been established for use in pre-menarchal females (girls who have not yet started menstruation). The results apply to the non-pregnant women populations studied in the primary trials.

Q: What should I look out for if I think I'm having a serious side effect?

Official warnings list symptoms such as bloody diarrhea, severe abdominal pain, and fever, and signs of severe allergic reactions (e.g., rash or swelling) as being associated with serious adverse effects like CDAD (colitis) or anaphylaxis.

Q: How are the clinical trials described in the official documents?

The official documents describe the pivotal trials as Randomized Controlled Trials (RCTs). These studies primarily monitored changes in three key indicators (vaginal pH, amine odor, and specific cells) as part of a composite outcome for assessing clinical status.

Q: Is it possible to have an overdose of the medication?

Official labeling addresses this possibility by stating that clindamycin phosphate applied vaginally could be absorbed in amounts sufficient to produce systemic effects (effects throughout the body). The ovules are administered in unit doses for local effect.

Q: Does this product contain any hormones?

No. The product is classified as a lincosamide antibiotic, an anti-infective agent. Official descriptions of its components and mechanism of action confirm it is an antibacterial drug that does not contain any hormonal substances.

How should Cleocin Vaginal Ovules be stored and disposed of?

Official Storage and Disposal Instructions

Cleocin Vaginal Ovules (clindamycin phosphate) must be stored at Controlled Room Temperature, specifically 25°C (77°F), with permissible temperature excursions ranging from 15°C to 30°C (59°F to 86°F). It is required to keep the product in the original container, tightly closed, and protected from high humidity. Do not freeze the ovules.

Storage Restriction	Requirement
Temperature	25°C (77°F); Avoid heat over 30°C (86°F)
Environment	Avoid freezing and high humidity
Safety	Keep out of the reach of children and pets

For disposal, unused or expired ovules should be managed through an official medicine take-back program. If one is unavailable, the product must be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a bag before being placed in the household trash. The ovules must not be flushed down a toilet.

Cleocin Vaginal Ovules